

July 25, 2017



Inogen to Announce Second Quarter 2017 Results on Thursday, August 3, 2017

GOLETA, Calif.--(BUSINESS WIRE)-- [Inogen, Inc.](http://www.inogen.com) (Nasdaq:[INGN](http://www.inogen.com)), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the second quarter of 2017 after market close on Thursday, August 3, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing (888) 317-6016 for domestic callers or (412) 317-6016 for international callers. Please reference Inogen (INGN) to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: <http://investor.inogen.com/>.

A replay of the call will be available beginning, August 3, 2017 at 3:30pm PT/6:30pm ET through 3:30pm PT/6:30pm ET on August 10, 2017. To access the replay, dial (877) 344-7529 or (412) 317-0088 and reference Access Code: 10110783. The webcast will also be available on Inogen's website for one year following the completion of the call.

Inogen has used, and intends to continue to use, its Investor Relations website, <http://investor.inogen.com/>, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit <http://investor.inogen.com/>.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170725006407/en/>

Inogen, Inc.

Investor Relations Contact:

ir@inogen.net

805-562-0500 ext. 7

or

Media Contact:

Byron Myers

805-562-0503

Source: Inogen, Inc.